Abstract
Abstract
Background
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of unknown etiology and unpredictable course. The aim of the work was to assess the levels of adropin, fibroblast growth factor-1 (FGF-1), and Toll-like receptor-1 (TLR1) biomarkers in IBD patients compared to controls and evaluate the gene expression of TNF-α as a marker of disease severity.
Methods
Adropin, fasting serum FGF-1 levels, TLR1, and TNF-α were measured in 60 IBD patients. They were also compared with 58 healthy controls matching age and gender. Moreover, the blood cells cDNA copy number of TNF-α were determined as a marker of severity.
Results
Adropin and TLR1 levels were significantly lower in patients than controls. FGF-1 was reduced but not statistically significant. The expression of TNF-α gene in the IBD patients was significantly increased (42%) in comparison with control samples (P < 0.001).
Conclusions
Adropin, IGF-I, and Toll-like receptor-1 biomarkers may have a role in the intricate pathophysiology of IBD and may possibly operate as predictors of disease activity. Thus, they may be therapeutic targets for IBD. Moreover, the expression of TNF-α gene can be used as a marker of severity.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Annese V (2020) Genetics and epigenetics of IBD. Pharmacol Res 159:104892
2. Jans D, Cleynen I (2023) The genetics of non-monogenic IBD. Hum Genet 1:1–14
3. Da Rio L, Spadaccini M, Parigi TL, Gabbiadini R, Dal Buono A, Busacca A et al (2023) Artificial intelligence and inflammatory bowel disease: Where are we going? World J Gastroenterol 29:508
4. Glassner KL, Abraham BP, Quigley EMM (2020) The microbiome and inflammatory bowel disease. J Allergy Clin Immunol 145:16–27
5. El-Atrebi KA, Taher E, El Aguizy FH, Ali RM, Hegazy A, El-Sayed MM, et al (2021) A descriptive study of inflammatory bowel disease at an Egyptian tertiary care center. Rev Gastroenterol México (English Ed 2021).